LONDON, June 4, 2026, 10:05 (BST)
- Mereo’s Nasdaq-listed ADS was last changing hands at $0.3342 in premarket, off $0.0104 from the last close.
- CEO Denise Scots-Knight will speak at the Jefferies Global Healthcare Conference later Thursday.
- Investors are trying to decide if the failed fracture endpoints for setrusumab will be balanced by gains in bone-density and other measures.
Mereo BioPharma Group plc’s U.S. shares were down in early premarket action Thursday with investors eyeing the rare-disease drug maker ahead of its spot at the Jefferies Global Healthcare Conference in New York. The ADSs changed hands at $0.3342 before Nasdaq’s regular hours.
No holiday for markets. Nasdaq’s premarket opens at 4:00 a.m. and goes until 9:30 a.m. Eastern. On its 2026 holiday calendar, the next June date the exchange is closed is Juneteenth, June 19, not this Thursday.
Mereo is under pressure to deliver more than broad updates. Shares are still trading near the low end of their $0.20 to $3.05 52-week range, with the company’s market cap at about $53 million. That’s well below where the stock stood before its late-2025 trial setback.
Mereo said June 2 that Scots-Knight is scheduled for a fireside chat at Jefferies at 9:55 a.m. EDT, or 2:55 p.m. BST. The company is offering an audio webcast, with a replay that will stay up for a month.
Setrusumab, Mereo’s candidate for osteogenesis imperfecta, is at the center of attention. Mereo said in December that two Phase 3 studies didn’t meet their main targets for reducing fracture rates, but both hit secondary goals tied to better bone mineral density, which measures bone strength.
Scots-Knight told investors in May there was a “basis to engage with the regulatory agencies” on a possible path in pediatric patients. She also said Mereo thinks setrusumab could give a “meaningful benefit” to people with osteogenesis imperfecta. The company says there aren’t any FDA- or EMA-approved therapies for the disease. Mereo BioPharma
Stock now faces a tight path—not a straight Phase 3 win, but looking to scrape value from secondary endpoints, subgroup work, and ongoing talks with regulators. For traders, any sign agencies might be open is enough to move shares. The price is low and premarket trading is thin.
Mereo’s cash pile gives it some breathing room, but the margin isn’t big. The company said it had $36.2 million in cash and cash equivalents as of March 31. It maintained its forecast for a cash runway into mid-2027 if it sticks to current plans.
Ultragenyx Pharmaceutical, which partners with Mereo on setrusumab and is a key rare-disease player in the program, traded at $22.41 recently, up 63.5 cents. The SPDR S&P Biotech ETF was at $129.83, up $2.08.
Mereo has alvelestat in its pipeline, aimed at alpha-1 antitrypsin deficiency-related lung disease. In May, the company said it was in active discussions with possible partners for Phase 3 development and commercialization. Management has said a partnership is important, and that a trial could kick off within six months of a deal closing.
But the risks are still big here. Regulators could say the fracture data don’t cut it, or Mereo may not land an alvelestat partner on investor-friendly terms. Any stumble would hit harder with Mereo’s microcap size, tight cash, and Nasdaq shares trading under $1. The company names clinical trial uncertainty, third-party reliance, and Nasdaq listing compliance as key risks.
Mereo shares are still down after December’s selloff, when the stock crashed on failed setrusumab studies and partner Ultragenyx dropped too. Back then, Mereo lost 90.3% in one day, cutting about $1.65 billion in market cap, according to MarketWatch.
